Stage II/III CRC: negative prognostic role for BRAF mutation

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In this meta-analysis, BRAF mutation was significantly associated with shorter disease-free survival (DFS) and overall survival (OS) among patients with stage II/III colorectal cancer (CRC) receiving adjuvant chemotherapy after curative resection.

Key results

  • Total of 7 phase ...